Tech Company Financing Transactions
Selecta Biosciences Funding Round
On 10/27/2011, Selecta Biosciences secured $22 million in Series D funding from private investors.
Transaction Overview
Company Name
Announced On
10/27/2011
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series D
Investors
Proceeds Purpose
Selecta will use the proceeds from these financings to accelerate its pipeline of products and expand the applications of its Synthetic Vaccine Particle (SVP). The company is expanding its capabilities by establishing a wholly-owned subsidiary in Moscow, Russia. The increased ability to grow Selecta's pipeline and improved international market access provide competitive advantages for Selecta to build its business.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/26/2011: Brammo venture capital transaction
Next: 10/27/2011: Napo Pharmaceuticals venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs